Immunoglobulin Sigardis (Solution) Instructions for Use
ATC Code
J06BA02 (Normal human immunoglobulin for intravenous administration)
Active Substance
Human normal immunoglobulin (Ph.Eur.)
Clinical-Pharmacological Group
Immunological preparation. Immunoglobulin
Pharmacotherapeutic Group
MIBP-globulin
Pharmacological Action
Human immunoglobulin, by replenishing the deficiency of antibodies, reduces the risk of developing infections in patients with primary and secondary immunodeficiency.
Indications
Congenital immunodeficiency conditions (congenital complete or partial immunodeficiency, common variable immunodeficiency, severe combined immunodeficiencies, Wiskott-Aldrich syndrome); idiopathic thrombocytopenic purpura (especially acute forms in children).
Acquired immunodeficiency (chronic lymphocytic leukemia, AIDS in children, bone marrow transplantation and other types of transplantation); Kawasaki syndrome (as an addition to acetylsalicylic acid therapy); prevention and therapy of infectious diseases.
ICD codes
| ICD-10 code | Indication |
| B24 | Human immunodeficiency virus [HIV] disease, unspecified |
| C91.1 | Chronic B-cell lymphocytic leukemia |
| D69.3 | Idiopathic thrombocytopenic purpura |
| D80 | Immunodeficiencies with predominant antibody deficiency |
| D81 | Combined immunodeficiencies |
| D82.0 | Wiskott-Aldrich syndrome |
| D83 | Common variable immunodeficiency |
| M30.3 | Mucocutaneous lymph node syndrome [Kawasaki] |
| Z29.1 | Prophylactic immunotherapy (administration of immunoglobulin) |
| Z94 | Presence of transplanted organs and tissues |
| ICD-11 code | Indication |
| 1C62.1 | HIV disease, clinical stage 2, without mention of tuberculosis or malaria |
| 2A82.00 | Chronic B-cell lymphocytic leukemia |
| 3B62.0Y | Other specified hereditary thrombocytopathies |
| 3B64.10 | Immune thrombocytopenic purpura |
| 4A01.0Y | Other specified immunodeficiencies with predominant antibody deficiency |
| 4A01.0Z | Immunodeficiencies with predominant antibody deficiency, unspecified |
| 4A01.1Z | Combined immunodeficiencies, unspecified |
| 4A44.5 | Mucocutaneous lymph node syndrome |
| QB63.Z | Presence of transplanted organ or tissue, unspecified |
| QC05.1 | Prophylactic immunotherapy |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer as an intravenous infusion only. Do not administer by bolus injection.
For primary immunodeficiency, administer a dose of 0.4-0.8 g/kg body weight every 3-4 weeks. Adjust the dose and interval to achieve a trough IgG level of at least 5-6 g/L.
For idiopathic thrombocytopenic purpura (ITP), administer a dose of 0.8-1.0 g/kg body weight. A second dose may be administered if required.
For chronic lymphocytic leukemia, administer a dose of 0.3-0.4 g/kg body weight every 3-4 weeks.
For Kawasaki syndrome, administer a single dose of 2.0 g/kg body weight in conjunction with acetylsalicylic acid.
For bone marrow transplantation, administer a dose of 0.5 g/kg body weight. Repeat doses weekly from one week before to three months after transplantation.
Initiate the first infusion at a rate of 0.5 mL/kg/hour. If well tolerated, gradually increase the rate every 30 minutes to a maximum of 4 mL/kg/hour.
For subsequent infusions, if the previous infusion was well tolerated, initiate at a rate of 1 mL/kg/hour and increase to a maximum of 4 mL/kg/hour.
Monitor the patient’s vital signs continuously throughout the infusion and for at least 20 minutes after its completion.
Discontinue the infusion immediately if adverse reactions occur. Resume at a slower rate only after symptoms have completely resolved.
Adverse Reactions
Headache, chills, increased body temperature, nausea, vomiting, joint pain, back pain, allergic reactions.
Rarely – decreased blood pressure, in isolated cases – anaphylactic shock, symptoms of aseptic meningitis (severe headache, nausea, vomiting, increased body temperature, neck stiffness, photophobia, impaired consciousness), worsening of renal failure in patients with impaired renal function.
Contraindications
Hypersensitivity, IgA deficiency in the presence of antibodies against IgA in the patient.
With caution pregnancy, lactation period.
Use in Pregnancy and Lactation
Use with caution during pregnancy and during lactation (breastfeeding).
Pediatric Use
Use is possible according to indications and in accordance with the dosage regimen.
Special Precautions
A temporary increase in the content of administered antibodies in the patient’s blood after immunoglobulin administration may cause false-positive results of serological tests.
The recommended infusion rate of the drug should not be exceeded (severe adverse reactions may develop). The patient must be under medical supervision throughout the entire infusion period and for 20 minutes after it.
Drug Interactions
Reduces the activity of attenuated live vaccines against measles, rubella, mumps, and varicella (if administered within the first 2 weeks after vaccination against measles, mumps, and rubella, vaccinations with these vaccines should be repeated no earlier than after 3 months).
Storage Conditions
Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for infusion 50 mg/ml: fl. 25 ml or 50 ml.
Marketing Authorization Holder
Siegardis Rus LLC (Russia)
Manufactured By
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
Dosage Form
| Immunoglobulin Sigardis | Solution for infusion 50 mg/ml: fl. 25 ml or 50 ml. |
Dosage Form, Packaging, and Composition
Solution for infusion colorless or light yellow, transparent or slightly opalescent.
| 1 ml | |
| Human normal immunoglobulin | 50 mg |
Excipients: dextrose – 50 mg, water for injections – up to 1 ml.
Theoretical osmolarity – 240 mOsm/l
25 ml – glass bottles (1) – cardboard boxes.
50 ml – glass bottles (1) – cardboard boxes.
Solution for infusion 50 mg/ml: fl. 100 ml.
Marketing Authorization Holder
Siegardis Rus LLC (Russia)
Manufactured By
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
Dosage Form
| Immunoglobulin Sigardis MT | Solution for infusion 50 mg/ml: fl. 100 ml. |
Dosage Form, Packaging, and Composition
Solution for infusion colorless or light yellow, transparent or slightly opalescent.
| 1 ml | |
| Human normal immunoglobulin | 50 mg |
Excipients: maltose – 100 mg, water for injections – up to 1 ml.
Theoretical osmolarity – 240 mOsm/l
100 ml – glass bottles (1) – cardboard boxes.
Arbidol, capsules 100mg, 40pcs
Cortexin, 10mg, 5ml, 10pcs
OKI, sachets 80mg 2g, 12pcs
Actovegin pills 200mg, 50pcs
Belosalic, lotion solution for external use spray 100ml
Cavinton Comfort, dispersible pills 10mg 90pcs
Picamilon pills 50mg, 60pcs
Ingavirin capsules 90mg, 10pcs
Nootropil pills 800mg, 30pcs
Belosalic, ointment, 30g
Mildronate capsules 500mg, 90pcs
Daivobet, ointment, 30g
Phenibut-Vertex pills 250mg, 20pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Kagocel pills 12mg, 30pcs
Noopept, pills 10mg, 50pcs 